Galapagos projects 2026 pivotal trials for GLPG5101 following FDA clearance
CEO Paul Stoffels highlighted 2024 as a pivotal year for Galapagos, emphasizing the FDA IND clearance for GLPG5101 and strong results from the ATALANTA study in non-Hodgkin lymphoma. He outlined the ...
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to ...
FierceBiotech5d
Galapagos drops one CD19 CAR-T to focus on 'flagship' program
Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...
Yahoo Finance6d
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
“With the FDA’s IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma ...
Yahoo Finance5d
Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update
“With the FDA’s IND clearance and the compelling clinical data we presented at ASH for our lead CD19 CAR-T candidate, GLPG5101, in three relapsed/refractory non-Hodgkin lymphoma indications, there is ...